At a recent forum in Seoul, SK Group unveiled its biotech investment strategy and noted the next few years could present multiple major opportunities for Korean biotechs.

BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.

Singapore- and US-based rational antibody design venture closes major new financing to support progress of its novel pipeline, with its two lead assets set to enter the clinic shortly. CEO Piers Ingram talks to Scrip about plans and strategy.

In tandem with buying the rest of Kleo, Tonix licenses molecular degradation technology from Yale. Neurogene, University of Dundee partner on cell therapies for neurological disorders.